SCHEMBL24399761

SCHEMBL24399761

Cc1ccc2c(Nc3ccc(Cl)c(F)c3F)nccc2c1NC(=O)c1cnc2c(N)ncnn12

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 12/20 0.56
▸ RAF1 P04049 9/20 0.56
▸ CSF1R P07333 5/20 0.56
▸ DDR1 Q08345 5/20 0.56
▸ DDR2 Q16832 5/20 0.56
▸ ARAF P10398 1/20 0.56
▸ MAPT P10636 1/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ CHRNA7 P36544 2/20 0.31
▸ ERN1 O75460 2/20 0.31
▸ ATR Q13535 2/20 0.31
▸ HDAC3 O15379 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29638586 1.00 BRAF (0.56) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399631 0.94 RAF1 (0.64) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638653 0.94 RAF1 (0.64) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638678 0.88 RAF1 (0.48) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL25378805 0.88 RAF1 (0.48) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL25373039 0.87 RAF1 (0.49) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638609 0.87 RAF1 (0.49) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399605 0.85 RAF1 (0.63) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL29638514 0.85 RAF1 (0.63) BRAFRAF1CSF1RDDR1DDR2
SCHEMBL24399719 0.84 RAF1 (0.48) BRAFRAF1CSF1RDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 — — US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 — — EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM BRAF 720/4885RAF1 2075/4885CSF1R 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback